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Abstract 
 
The first MURIA (Medicines Utilisation Research in Africa) group workshop and symposium brought 
researchers together from across Africa to improve their knowledge on drug utilisation (DU) 
methodologies as well as exchange ideas. As a result, progress DU research to formulate future 
strategies to enhance the rational use of medicines. Anti-infectives was the principal theme for the 
one day symposium following the workshops. This included presentations on the inappropriate use of 
antibiotics as well as ways to address this. Concerns with adverse drug reactions and adherence to 
anti-retroviral medicines was also discussed, with poor adherence remaining a challenge. There were 
also concerns with the underutilisation of generics. These discussions resulted in a number of agreed 
activities before the next conference in 2016. 
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Manuscript 
 
MURIA is a multidisciplinary research group striving to promote sustainable, rational medicine use in 
Africa (1). Activities include the first MURIA workshop and symposium held at the University of 
Botswana from 27th to 29th July 2015 (1). This was opened by the Deputy Vice Chancellor of 
Academic Affairs (Prof Totolo) and the Minister of Health, Hon Dorcas Makgato. Hon Dorcas Makgato 
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emphasised the importance of addressing the potential misuse of antibiotics as well as critically 
looking at antiretroviral (ARV) medicines, non-communicable diseases (NCDs) and generic 
medicines. Anti-infectives and NCDs are also of particular importance globally. She stressed that we 
can only act on data, facilitated by cross-national studies. 
 
Delegates subsequently attended either introductory or advanced workshops. Ilse Truter opened the 
Introductory Group workshop by giving an outline of key issues for drug utilisation (DU) research 
including guidelines, types of research, data sources and classification systems (2, 3) as well as 
giving examples. Margaret Oluka expanded on this by discussing the Anatomical Therapeutic 
Chemical /Defined Daily Dose (ATC/DDD) classification in more detail including DDDs/ 1000 
inhabitants/ day (DIDs) to assess DU across countries. Olayinka Ogunleye discussed developing 
standardised indicators, which included together with goals: (i) average number of medicines 
prescribed/ patient encounter (<2), (ii) % medicines prescribed by generic name (close to 100%); (iii) 
% encounters prescribed an antibiotic (<30%); (iv) % encounters with an injection prescribed (<10%); 
(v) % medicines prescribed from an essential medicines list (EML) or formulary (close to 100%).  
 
Brian Godman closed the morning session by discussing ways to influence the rational use of 
medicines, broken down into the 4Es ± education, economics, engineering and enforcement (4).  
Multiple measures have enhanced the prescribing of generic versus patented statins, ACEIs versus 
patented angiotensin receptor blockers (ARBs), and generic versus patented ARBs (5, 6) as well as 
reduced antibiotic utilisation (7). Day one for the Introductory Group ended with Marike Cockeran 
discussing basic statistics applied to DU research.  
 
Andy Gray open the Advanced Group workshop by discussing key issues concerning antibiotic DU 
research, with potential alternatives including DDDs/ 100 bed days/ unit of time and DDDs/ 100 
patient encounters/ unit of time (8). Potential data sources vary by country, and include both private 
and public sectors as well as data from surveys (9). Matthias Adorka subsequently discussed novel 
approaches to DU research including developing new methodologies to assess appropriate antibiotic 
prescribing (10). Brent Knoesen then discussed key principles involved with undertaking qualitative 
research, including when it should be undertaken and potential applications in DU research.  
 
Challenges for cross-national studies include using standard utilisation methods, the same protocol, 
robust datasets, working with health authorities to accurately document country measures and 
ensuring a good mix of countries and interventions to enhance future learnings (5, 6, 11). Johanita 
Burger discussed pharmacoeconomics including the four basic study approaches alongside 
examples. Finally, Theunis Kotze ended the first day by discussing advanced statistical methods.  
 
Day two for the Introductory Group started with Rianda Joubert discussing applications of DU 
research including quantitative and qualitative studies, e.g. questionnaires among physicians in 
Namibia ascertained first-line treatment of patients with upper respiratory tract infections (URTIs) was 
typically amoxicillin with clavulanic acid and ciprofloxacin for urinary tract infections (UTIs), against 
recommended Namibian guidelines (12). Household surveys are also an important source of DU data 
in Africa, especially where there is appreciable self-purchasing of medicines (13). Finally Andy Gray 
discussed the basic principles of medical and research ethics including the need for ethics in 
research, basic biomedical research principles, informed consent, the need for transparency as well 
as the challenges involved in retrospective and epidemiological research.  
 
Lars Gustafsson started the second morning for the Advanced Group by exploring drug safety and the 
use of databases in DU research, especially with limited knowledge about adverse drug reactions 
(ADRs) in a number of countries (14). Examples include early warning indicators for HIV drug 
resistance (15), the use of open source clinical trials software systems (16), and the comprehensive 
longitudinal database regarding HIV therapy and its outcome in Botswana during the past decade 
(17). Interdisciplinary groups working together analysing, communicating their findings and follow-up 
DU in practice are all important considerations for changing prescribing behaviour. This is seen in 
6WRFNKROP6ZHGHQZLWKKLJKDGKHUHQFHUDWHVWRWKHµ:LVH/LVW¶WKURXJKDFRPSUHKHQVLYH approach 
and physician trust in those developing the formulary of just over 200 medicines in ambulatory care 
(18). The advanced workshop ended with Joseph Fadare leading discussions regarding ethics, 
especially key issues and challenges. This was illustrated with examples (19).   
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Anti-infectives were the principal theme of the oral and poster sessions for the symposium. A 
qualitative study among households in Kampala revealed the common cold was the most prevalent 
acute respiratory infection. There was high use of antibiotics at 43% of cases, mainly amoxicillin and 
cotrimoxazole, before seeking medical care, with a strong correlation between antibiotic use, 
presence of pneumonia symptoms, level of education of the caregiver and the source of medicines. 
Johanita Burger presented findings from a study conducted by Agyakwa and colleagues, who found 
high prescribing of fluoroquinolones by physicians in the private healthcare sector in South Africa, 
representing 28% of all antibiotic prescriptions (20). Qualitative research undertaken by Thatoyaone 
Kenaope and colleagues found among pharmacists in South Africa, the socio-economic status of 
patients, patient satisfaction, their knowledge of antibiotic indications and the professional relationship 
between healthcare professionals influenced physician prescribing behaviour. Consequently, there is 
a need to target all stakeholder groups to improve antibiotic use. 
 
The irrational use of antibiotics was also seen among government facilities in Swaziland, with 
respiratory tract infections as the most common diagnosis. This led to suggestions that the 
government should strengthen hospital drugs and therapeutic committees as well as antibiotic 
management programmes. A retrospective study carried out by Bene Paramadhas and Tennyson 
Mgutshini among HIV-infected patients at a tertiary care facility in Botswana revealed a high degree of 
empiric prescribing with culture and sensitivity tests rarely ordered. There was a high degree of IV 
antibiotics prescribed at 52% of prescriptions, with only a limited number switched to oral medicines. 
Positively, all antibiotics prescribed were on the Botswana EML, and 86% of all antibiotics were 
prescribed by their generic name. Further studies and interventions and planned to address concerns. 
There are also plans in Botswana to undertake DU studies among private physicians treating patients 
for URTIs following the publication of tnational guidelines in 2012. This will form the basis of future 
measures.  
 
Mwanga Mubita and colleagues found the implementation of a multifaceted antimicrobial care 
DSSURDFKDURXQGµ6WDUWVPDUWWKHQIRFXV¶LQDQ,QWHUQDO0HGLFLQHZDUGDWD8QLYHUVLW\7HDFKLQJ
Hospital in Zambia led to  improvements in the quality of antimicrobial prescribing in terms of 
compliance with the outlined care elements. Multifaceted approaches have also worked in other 
countries (7). 
 
There are also concerns regarding ADRs and adherence to ARVs. Francis Kalemeera and colleagues 
XVLQJ1DPLELD¶V$GYHUVH5HSRUWLQJGDWDEDVH± VigiFlow® ± ascertained that a nevirapine safety 
signal was detected after shifting the initiation of nevirapine to patients with higher CD4-counts than 
previously recommended. This resulted in the Ministry of Health in Namibia halting this move, 
demonstrating that locally derived ADR data can protect patients. This is important as the 
characteristics of patients with HIV in Africa are different from those in Europe and the US.  
 
Razia Gaida discussed a systematic review of efavirenz and its side-effects that she and colleagues 
had undertaken (21). They found a total of 13 articles between 2001 and 2014, and concluded that as 
efavirenz does not commonly induce severe side-effects that warrant discontinuation, it can be 
considered for use in psychiatric patients.  
 
Poor adherence remains a major challenge in patients, especially those on highly active antiretroviral 
therapy (HAART). Contributing factors include ADRs with HAART, high tablet count (typically >4) and 
lower earnings as discussed by Norah Katende. Current adherence rates to ARVs are also being 
followed up in Botswana following national guidelines changing ARV eligibility to better plan for the 
future.  
 
There were also presentations on other disease areas. Pauline van Zyl undertook a study to examine 
the prevalence and co-morbidity of irritable bowel syndrome (IBS), depression and anxiety amongst 
retirement village residents in South Africa using a variety of questionnaires. Overall, there was a 
lower than expect rate of IBS. However, the majority of participants using antidepressants, anxiolytics 
and PPIs were taking these for one year or longer, with participants taking PPIs or antidepressants 
more likely to experience IBS symptoms.  
 
Adedunni Olusanya assessed the effects of co-administration of other drugs on compliance, ADRs 
and seizure control in patients taking carbamazepine monotherapy for epilepsy. She found that 
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compliance was significantly lower in patients co-administered with other medicines; however, there 
was no significant difference in seizure control or reports of ADRs.  Studies showed there are 
concerns with generic medicines in a number of African countries. Joseph Fadare and colleagues in 
Nigeria identified a number of gaps in physician perception of generics and their prescribing and 
dispensing. Margaret Oluka found prescribing of generics was sub-optimal at only 52% of 
prescriptions in an outpatient department of a national referral hospital in Kenya. Both need to be 
addressed before key stakeholders benefit from low cost generics.  
 
Finally, there are ongoing initiatives to progress collaboration between centres in Africa through 
simplifying processes, thereby strengthening both capacity for drug development and RUM in Africa 
(22). 
 
The feedback from the meeting was positive with attendees typically finding workshop presenters 
knowledgeable in their areas, with the content relevant to their needs. In addition, the information 
could be applied to their workplace. The main criticism was not enough time to debate key issues and 
their implications.  
 
A number of activities are planned for 2015/ 2016, and we look forward to the second MURIA Group 
meeting in Botswana in July 2016. 
 
All abstracts, workshop presentations including planned projects in 2015/ 2016 and  the speech by 
the Minister of Health can be found on: http://muria.nmmu.ac.za/Botswana-Workshop-and-
Symposium-27-29-July-2015. MURIA membership forms can be found on: 
http://muria.nmmu.ac.za/Membership.  
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